Our newest offerings and capabilities. Recent investments in network capacity, new and expanded services and expertise. Upcoming conferences and events.
Updates for media on the latest products, offerings and developments across our business.
Jul 16, 2019
Catalent Biologics today announced a long-term strategic agreement for the development and manufacturing of Zolgensma® (onasemnogene abeparvovec-xioi), an AveXis gene therapy treatment for spinal muscular atrophy (SMA).
Jul 10, 2019
Catalent today announced that Cornell Stamoran, Ph.D., founder of Catalent’s Applied Drug Delivery Institute, has been invited to chair multiple sessions at the upcoming CRS Annual Meeting and Exposition in Valencia, Spain.
Jul 10, 2019
The dedicated cGMP suite is to be built under strategic partnership with Paragon Gene Therapy to support future clinical and commercial production for Passage Bio’s AAV-delivered gene therapies
Jul 9, 2019
Catalent today announced that it has significantly expanded the capacity of its global spray drying operations through an agreement with Sanofi Active Ingredient Solutions, an industrial platform of Sanofi…
Jul 2, 2019
Catalent today announced that Ben Kester, Manager and Senior Scientist, Purification Development, Catalent Biologics, will present at the upcoming 32nd International PREP Symposium.
Jul 2, 2019
The agreement supports clinical and commercial supply needs for Pompe and other lysosomal disease gene therapy programs
Jun 27, 2019
Catalent today announced that Rob Harris, Ph.D., Director, Science & Technology will present at the upcoming ON Helix conference to be held at the Babraham Research Campus, Cambridge, U.K. on July 9 – 10, 2019.
Jun 27, 2019
Novavax, Inc. and Catalent Biologics’ Paragon Gene Therapy unit today announced an arrangement under which Paragon Gene Therapy will assume the leases to two Novavax product development and manufacturing facilities, giving it immediate access to state-of-the-art…
Jun 19, 2019
Bristol-Myers Squibb Company and Catalent, Inc. today announced that Catalent has agreed to purchase Bristol-Myers Squibb’s oral solid, biologics, and sterile product manufacturing and packaging facility in Anagni, Italy.
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
